Argitalpenak (106) MIGUEL ÁNGEL CALLEJA HERNÁNDEZ argitalpenak

2024

  1. Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy—A Hospital-Based Prospective Observational Study

    Journal of Clinical Medicine, Vol. 13, Núm. 4

2023

  1. Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer: A Systematic Review of Trials Published Between 2010 and 2020

    American journal of clinical oncology, Vol. 46, Núm. 10, pp. 433-438

  2. Medication Review with Follow-Up for End-Stage Renal Disease: Drug-Related Problems and Negative Outcomes Associated with Medication—A Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 15

2021

  1. Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1

    Acta Oncologica, Vol. 60, Núm. 9, pp. 1225-1232

  2. Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis

    Pharmacogenetics and Genomics, Vol. 31, Núm. 2, pp. 40-47

  3. Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives

    Mutation Research - Reviews in Mutation Research, Vol. 788

  4. Impact of a risk-sharing agreement in rheumatoid arthritis in Spain

    Health Policy, Vol. 125, Núm. 3, pp. 335-340

  5. Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis

    Molecular Neurobiology, Vol. 58, Núm. 9, pp. 4716-4726

  6. Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis

    Journal of Personalized Medicine, Vol. 11, Núm. 5

2020

  1. Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis

    Pathology Research and Practice, Vol. 216, Núm. 4

  2. Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta

    Mutation Research - Reviews in Mutation Research, Vol. 785

  3. Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program

    Journal of Infection and Public Health, Vol. 13, Núm. 4, pp. 558-563

  4. Randomized, double-blind, controlled trial, phase III, to evaluate the use of platelet-rich plasma versus hyaluronic acid in hip coxarthrosis

    Revista Espanola de Cirugia Ortopedica y Traumatologia, Vol. 64, Núm. 2, pp. 134-142

2019

  1. Clinical outcomes of carbapenem de-escalation regardless of microbiological results: A propensity score analysis

    International Journal of Infectious Diseases, Vol. 85, pp. 80-87

  2. Clinical pharmacy services: From cost-effectiveness analysis to a productivity indicators model

    European Journal of Hospital Pharmacy

  3. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients

    Pharmacogenomics Journal, Vol. 19, Núm. 2, pp. 164-177

  4. Trends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study

    Thoracic Cancer, Vol. 10, Núm. 4, pp. 904-908

2018

  1. 10 temas candentes en farmacia oncohematológica

    Sociedad Española de Farmacia Hospitalaria

  2. Hospital pharmacy and critical care medicine: A necessary alliance

    Farmacia Hospitalaria

  3. Hospital pharmacy and critical care medicine: A necessary alliance

    Biomedical Instrumentation and Technology